Depletion of anti-CD47mAb in plasma by genetically modified cells for pre-transfusion testing  

作　　者：Fei Wang Wenting Wang Xiaoshuang Wu Zhixin Liu Yafen Wang Rong Zhang Shunli Gu Qunxing An Yaozhen Chen Xingbin Hu 

机构地区：[1]Department of Transfusion Medicine,Xijing Hospital,Fourth Military Medical University,Xi’an,Shaanxi 710032,China [2]Xi’an Medical University,Xi’an,Shaanxi 710021,China

出　　处：《Genes & Diseases》2024年第5期102-104,共3页基因与疾病（英文）

摘　　要：Allogeneic red blood cell(RBC)transfusion is commonly performed in medical practice because of its efficacy and low-risk level.However,pre-transfusion tests are susceptible to monoclonal antibody(mAb)interference.1 Currently,mAb therapies are being developed to treat many diseases,such as cancer.However,certain mAbs,such as anti-CD38mAb and anti-CD47mAb,can bind to RBC membranes;this binding interferes with pre-transfusion tests.2 CD47 has gained considerable attention in recent years because of its potential as a therapeutic target for hematologic malignancies and solid tumors.3 The binding of anti-CD47mAb to RBCs may lead to false-positive results in pan-agglutination tests and cause delays and risks in establishing compatible RBCs for transfusion.

关 键 词：CD47 TRANSFUSION DISEASES 

分 类 号：R457.1[医药卫生—治疗学]